# CRBP — Corbus Pharmaceuticals Holdings Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CRBP  
**Sources:** 19  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-crbp-corbus-pharmaceuticals-holdings-inc-catalysts-narra-10543

---

## Company Profile

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biotech headquartered in Norwood, Massachusetts, focused on oncology and obesity. Its pipeline includes CRB-701 (a Nectin-4-targeting antibody-drug conjugate), CRB-601 (an anti-integrin monoclonal antibody blocking TGFβ), and CRB-913 (an oral, peripherally restricted CB1 receptor inverse agonist for obesity). The company has no marketed products and no stable revenue stream [[10]](https://ir.corbuspharma.com/news-events/press-releases), [[16]](https://finance.yahoo.com/healthcare/articles/crbp-good-cannabis-investment-positive-130000518.html), [[19]](https://ir.corbuspharma.com/). As of late October 2026 the stock had a market capitalization of ~$81.6M, a 52-week range of $3.87–$17.24, and a beta of 2.79 [[15]](https://stockanalysis.com/stocks/crbp/).

## Key Recent Catalysts (last ~1–3 months, as of 2026-11-01)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-crbp-corbus-pharmaceuticals-holdings-inc-catalysts-narra-10543 (free to sign up)._